New Alzheimer's Antibody Shows Promise in Slowing Memory Decline, Biogen Submits IPO Prospectus
Alzheimer’s Drug Trial Results: Yellow Indicates β-Amyloid Plaques in the Brain
Pharmaceutical companies have invested billions in developing drugs to prevent and reduce the buildup of pathological plaques (an abnormal brain tissue known as beta-amyloid), but repeated clinical trial failures have led many to question the feasibility of this approach.
Latest Research Findings Announced: A Major Breakthrough in Alzheimer’s Disease TreatmentRecent research findings have been announced, marking what is considered a significant victory in the field of Alzheimer’s disease treatment. Trial data indicate that aducanumab, an anti-amyloid-beta monoclonal antibody drug, can slow cognitive decline in the early stages of Alzheimer’s disease. However, as this study was limited to an early-phase safety trial, its feasibility remains difficult to confirm, leading many to dismiss it as merely another pipe dream.
The research team published a report in Nature, which included nearly all of their data and referenced events such as the 2015 Alzheimer’s Association International Conference in Washington, providing “comprehensive, coherent, and meticulously reviewed data.” Stephen Salloway, a neurologist at Brown University and one of the researchers, stated, “This is the first time a beta-amyloid-lowering drug with potential clinical value has been identified.”
For years, pharmaceutical companies and academic researchers have competed to develop anti-β-amyloid drugs, eager to identify the root causes of clinical failures while hoping that their years of research were not based on a fundamental misunderstanding of Alzheimer’s disease. To address potential issues, they have tried many β-amyloid–targeting strategies aimed at preventing its accumulation and removing plaques formed in the early stages of the disease through early intervention. Aducanumab, an antibody produced by Biogen, can capture and remove β-amyloid deposits in the brain. According to Salloway, its origin is quite unique, derived from healthy elderly individuals who are naturally resistant to Alzheimer’s disease.。
In a year-long trial, 165 patients with Alzheimer’s disease who had mild cognitive impairment or dementia participated. Researchers administered monthly doses of aducanumab at 1, 3, 6, or 10 mg/kg to participants, while another group received a placebo. After 54 weeks, positron emission tomography (PET) brain scans revealed that patients receiving lower doses had less β-amyloid deposition, and the reduction in deposition was greater with higher doses. “This is a remarkable achievement and significant progress in the field,” said Robert Vassar, a neurologist at Northwestern University’s Feinberg School of Medicine in Chicago, describing it as a major breakthrough.
More encouragingly, new experiments have also yielded signs favorable to cognition. Participants receiving the maximum dose of 10 mg exhibited a one- to two-fold reduction in protein deposition compared to those receiving lower doses or placebo.
However, it is concerning that 40 participants withdrew from the trial midway due to adverse effects such as minor hemorrhages and cerebral edema. The higher the dose, the more pronounced the side effects. This has been a long-standing and deeply troubling issue for researchers developing beta-amyloid vaccines, as these vaccines can trigger dangerous brain inflammation.
In summary, Alzheimer’s disease researchers are urging caution regarding the new drug results. A major limitation of this study was the lack of participant screening, leaving uncertainty about which individuals are suitable for such treatment, noted Dr. David Knopman, a neurologist at the Mayo Clinic in Minnesota. Another larger-scale Phase III clinical trial, spanning 18 months, is currently underway. Researchers hope this trial will determine whether the treatment is effective in a more diverse population, addressing a common challenge in the development of many Alzheimer’s drugs.